Evidence map›Paper›PMID 27579999›Full record

ArticleAlcoholism, clinical and experimental research2016

Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice.

Gunnar Sørensen, S Barak Caine, Morgane Thomsen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alcoholism, clinical and experimental research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 4 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Observational
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Gunnar SørensenAlcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical School, Belmont, Massachusetts. gsorensen@mclean.harvard.edu.
S Barak CaineAlcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical School, Belmont, Massachusetts.
Morgane ThomsenAlcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical School, Belmont, Massachusetts.
McLean Hospital · USHarvard University · US

Funding

Development of an Implantable On-Demand Drug Delivery Device for Behavioral Studies in Small AnimalsR44DA041173 · NIDA · SFC FLUIDICS, LLC · PI PAYNE, FORREST · 2017 to 2018
$1.5M
Selective Muscarinic Receptor Ligands as Targets for Cocaine Addiction MedicationR00DA027825 · NIDA · MCLEAN HOSPITAL · PI THOMSEN, MORGANE HERMANN · 2012 to 2014
$710k
Selective Muscarinic Receptor Ligands as Targets for Cocaine Addiction MedicationK99DA027825 · NIDA · MCLEAN HOSPITAL · PI THOMSEN, MORGANE HERMANN · 2010 to 2011
$247k
Development of an Implantable On-Demand Drug Delivery Device for Behavioral Studies in Small AnimalsR43DA041173 · NIDA · SFC FLUIDICS, LLC · PI PAYNE, FORREST · 2015 to 2016
$215k
NIDA NIH HHS K99 DA027825NIDA NIH HHS R00 DA027825NIDA NIH HHS R43 DA041173NIDA NIH HHS R44 DA041173
6 · The paper itself

Abstract

backgroundGlucagon-like peptide 1 (GLP-1) receptor agonists have been shown to decrease ethanol (EtOH) drinking in rodent assays. The GLP-1 system also powerfully modulates food and fluid intake, gastrointestinal functions, and metabolism. To begin to understand the neurobiological mechanisms by which GLP-1 receptor ligands may be able to control EtOH intake, it is important to ascertain whether they can modulate the direct reinforcing effects of EtOH, without the confound of effects on ingestive behaviors generally.

methodsWe trained experimentally naïve, free-fed C57BL/6J mice to self-administer EtOH intravenously. Once stable EtOH intake was acquired, we tested the effect of acute pretreatment with the GLP-1 receptor agonist Exendin-4. Effect of Exendin-4 on operant behavior reinforced by a palatable liquid food was similarly evaluated as a control.

resultsIntravenous EtOH functioned as a positive reinforcer in over half the mice tested. In mice that acquired self-administration, EtOH intake was high, indeed, reaching toxic doses; 3.2 μg/kg Exendin-4 decreased intravenous EtOH intake by at least 70%, but had no significant effect on food-maintained operant responding.

conclusionsThis experiment produced 2 main conclusions. First, although technically challenging and yielding only moderate throughput, the intravenous self-administration procedure in mice is feasible, and sensitive to pharmacological manipulations. Second, GLP-1 receptor agonists can powerfully attenuate voluntary EtOH intake by directly modulating the reinforcing effects of EtOH. These findings support the potential usefulness of GLP-1 receptor ligands in the treatment of alcohol use disorder.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsAdministration, IntravenousAnimalsConditioning, OperantEthanolExenatideFoodMaleMicePeptidesRewardSelf AdministrationVenomsEthanolExenatideGlucagon-Like Peptide-1 Receptor AgonistsPeptidesVenomsAlcoholExendin-4Glucagon-Like Peptide 1Intravenous Self-AdministrationMouse

Identifiers

PMID27579999
PMCPMC5048549
OpenAlexW2514621876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.